Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

- The report reviews pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects

- The report assesses Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlfaSigma SpA

AnGes Inc

ARCA biopharma Inc

Athera Biotechnologies AB

Athersys Inc

Bayer AG

Betagenon AB

BiogenCell Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Diffusion Pharmaceuticals ...

AlfaSigma SpA

AnGes Inc

ARCA biopharma Inc

Athera Biotechnologies AB

Athersys Inc

Bayer AG

Betagenon AB

BiogenCell Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Diffusion Pharmaceuticals Inc

Hemostemix Inc

Human Stem Cells Institute

ID Pharma Co Ltd

Juventas Therapeutics Inc

LipimetiX Development Inc

Novartis AG

Proteon Therapeutics Inc

Recardio GmbH

Resverlogix Corp

Reven Pharmaceuticals Inc

Stemedica Cell Technologies Inc

Symic Biomedical Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Overview 6

Peripheral Arterial Disease (PAD)/ Peripheral Vascular ...

Table of Contents

Table of Contents 2

Introduction 5

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Overview 6

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Therapeutics Development 7

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Therapeutics Assessment 18

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Companies Involved in Therapeutics Development 26

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drug Profiles 38

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects 169

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products 174

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Product Development Milestones 175

Appendix 191

List of Tables

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2018

Number of Products under Development by ...

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AlfaSigma SpA, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AnGes Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ARCA biopharma Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athera Biotechnologies AB, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athersys Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Bayer AG, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Betagenon AB, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by BiogenCell Ltd, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by CardioVascular BioTherapeutics Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Celularity Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Diffusion Pharmaceuticals Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Hemostemix Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Human Stem Cells Institute, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ID Pharma Co Ltd, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Juventas Therapeutics Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LipimetiX Development Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Novartis AG, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Proteon Therapeutics Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Recardio GmbH, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Resverlogix Corp, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Reven Pharmaceuticals Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Stemedica Cell Technologies Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Symic Biomedical Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by VESSL Therapeutics Ltd, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ViroMed Co Ltd, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Yuyu Pharma Inc, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, H2 2018 (Contd..1), H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, H2 2018 (Contd..2), H2 2018

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2018

Number of Products under Development by ...

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports